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1. Introduction 
Protein A from Staphylococcus aureus reacts with 
the Fc fragment (**) of all mammalian IgG’s that have 
been tested thus far [l-4] . Protein A elicits Arthus 
reactions in rabbits pretreated with normal human im- 
munoglobulin [S] , anaphylaxis in normal guinea pigs 
[6] and erythema-wheal reactions in man [7]. The 
Arthus reaction is known to be mediated by comple- 
ment [8]. Whether the complement system is involved 
in anaphylactic reactions is uncertain, but it is known 
to generate vasoactive substances from tissues [9]. The 
effect of protein A-IgG complexes on the complement 
system has been investigated and it was found that such 
complexes inactivate complement in a way similar to 
that of an antigen-antibody complex [lo-l 21. 
The complement factor existing in highest concentra- 
tion in serum is C3a [9] . During activation of the com- 
plement system, this protein is split into two frag- 
ments by C3 convertase, Ca [9]. The smaller frag- 
ment released, C3a, has anaphylatoxic activity. The 
larger fragment has a higher electrophoretic mobility 
than C3 at neutral pH. Conversion of C3 proves that 
enzymatic activity has been induced in serum provided 
that the material under consideration does not have en- 
zymatic activity in itself. Protein A added to human 
serum gives rise to C3 conversion. It does not affect puri- 
fied C3, however, and the conversion in whole serum is 
not a result of enzymatic action of protein A on factor 
c3. 
* Part XII of a series. 
** Abbreviations for immunoglobulins, complement and com- 
plement factors conform with the rules suggested in [22] 
and (231. 
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2. Materials and methods 
Protein A was purified from lysozyme-digested 
S. aureus as previously described [ 121. 
Fresh individual human sera, stored at -2O”, were 
used. 
Anti-C3 serum was produced in rabbits by immuni- 
sation against zymosan-absorbed human factor C3. 
The antiserum was kindly supplied by Dr. K.-E. Fjell- 
Strom, Dept. of Medicine, Uppsala Akademiska Sjuk- 
hus. The antiserum was stored at 4” with 0.01% NaNs 
as preservative. 
Human IgG was a Cohn fractionated preparation 
(Kabi AB, Stockholm). 
Immunoelectrophoresis was performed on micro- 
scope slides [ 131 in one percent agarose (l’lndustrie 
Biologique Francaise S.A.) 0.01 M tris-acetic acid, 
pH 8.0. The electrophoresis was run for 90 min at 
50 V. Antiserum, 50 1.11, was added and the precipitates 
formed were examined and photographed after 24 hr. 
Human complement factor C3 @lC) was prepared 
as described by Nilsson and Miiller-Eberhard [ 141, 
omitting the last step, the preparative block electro- 
phoresis. C3 was purified from the euglobulin fraction 
of human serum by chromatography on TEAE cel- 
lulose and hydroxyl apatite columns, in that order. 
This partially purified C3 gave only one precipita- 
tion line in immunoelectrophoresis with goat anti- 
serum against human serum proteins (Kabi AB, Stock- 
holm). In polyacrylamide disc electrophoresis, 7% gel, 
pH 8.9 [ IS], three bands appeared, one strong band 
and one weak band on each side of this. 
Trypsin digestion of purified C3 was performed ac- 
cording to Bokisch et al. [ 161 using 2 mg C3 per ml. 
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Fig. 1. Conversion of factor C3. Equal volumes of a) human 
serum and 0.04% protein A; b) human serum and VBS; c) 
0.35% purified human C3 and 0.025% protein A; d) 0.35% 
purified human C3 and VBS. All mixtures were incubated at 
37” for 60 min prior to electrophoresis; e) purified human C3 
(0.2% concentration) treated with trypsin. Soybean trypsin in- 
hibitor was subsequently added. Immunoelectrophoresis devel- 
oped with rabbit antiserum against human C3. Anode to the 
right. For details see text. 
3. Results 
To 50 ~1 aliquots of human serum, l- 1000 pg pro- 
tein A was added in 50 ~1 Verona1 buffered saline (VSB) 
[ 171. In a control, 50 ~1 VBS was added to 50 /..d serum. 
The samples were incubated at 37” for 60 min. EDTA 
was then added to a final concentration of 0.01 M to 
prevent nonspecific conversion. After centrifugation, 
5 ~1 of each sample was used in immunoelectrophoresis 
(fig. 1). Material migrating faster than the serum con- 
trol appeared in all cases. This indicated that conversion 
had taken place even following the addition of 1 pg 
protein A. 
To test whether protein A has any direct effect on 
factor C3, partially purified C3 was used. One volume 
of 0.35% C3 in phosphate buffer pH 7.0, /.L = 0.1, was 
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mixed with one volume 0.025% protein A. The mixture 
was incubated at 37” for 60 min and 5 1.11 was used 
for immunoelectrophoresis (fig. 1). This treatment 
did not cause any change in the electrophoretic mobil- 
ity of C3. Aggregates of protein A and purified human 
IgG were used in one experiment. Equal volumes of 
1% human IgG and 0.05% protein A were mixed and 
incubated at 37” for 90 min and at 4” overnight. The 
precipitate formed was spun down and suspended in 
100 ~1 VBS. To 50 /.d 0.35% C3,50 ~1 of this suspen- 
sion was added. After incubation at 37’ for 60 min 
no conversion of C3 was detected by immunoelectro- 
phoresis against anti-C3 serum. When the same amount 
of IgG-protein A aggregates was added to human serun 
conversion occurred. Treatment of factor C3 with 
trypsin for 60 set at 20” resulted in a product with 
the same electrophoretic mobility as that after treat- 
ment of serum with protein A (fig. 1). 
4. Discussion 
In earlier investigations it has been found that 
protein A from S. aureus is able to elicit hypersensi- 
tivity reactions. At least in the Arthus reaction, acti- 
vation of complement is known to be involved. It has 
also been shown that protein A-IgG complexes fix 
complement in vitro. There are a number of substan- 
ces such as zymosan [17], NH3 [17], NHzOH [18] 
endotoxin [ 191 and cobra venom factor [20] which 
affect the complement system but not in the same 
way as an antigen-antibody complex. 
To obtain information as to how protein A-IgG 
complexes act on the complement system, their ef- 
fect on factor C3 was studied. When protein A is ad- 
ded to human serum, C3 is converted. However, pro- 
tein A or aggregates of protein A and IgG do not 
bring about the conversion of purified C3. The most 
probable explanation for the C3 conversion observed 
is that Cl acts on factors C4 and C2, resulting in for- 
mation of C3 convertase, Co. Cl is probably ac- 
tivated by fixation to the protein A-IgG complex. 
This complex, which is formed by the reaction of pro- 
tein A with the Fc part of IgG, would then have the 
same effect on the complement system as an ordinary 
antigen-antibody complex. This interpretation would 
explain the results presented by Kronvall and Gewurz 
[ 111, who observed a decrease of all complement 
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factors after addition of protein A to serum. (71 R.R. Martin, J.G. Crowder and A. White, J. Immunoi. 
ment system. This seems to occur with complexes of 
It is possible, however, that the C3 conversion ob- 
served is mediated by the action of the protein A-IgG 
guinea pig IgGl and homologous antigen [21]. However, 
complex on serum components outside the comple- 
[9] H.J. MiiIIer-Eberhard, Ann. Rev. Biochem. 38 (1969) 389. 
99 (1967) 269. 
[lo] J. SjGquist and G. Stlilenheim, J. Immunol. 103 (1969) 
(81 C.G. Cochrane in: The Inflammatory Process, eds. B.W. 
Zweifach, L. Grant and R.T.McCluskey (Academic Press, 
New York, London, 1965). 
the results of Kronvall and Gewurz [ 111 would seem 
to reduce the likelihood of this possibility. 
461. 
[ 111 G. KronvaIl and H. Gewurz, Clin. Exptl. Immunol. 7 
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